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This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based 
research. The summary is not intended to be a comprehensive summary of available evidence on 
COVID-19 but aims to make original documents easily accessible to decision makers which, if 
relevant to them, they should go to before making decisions. 




















• A highly effective 
transmission-blocking 
vaccine prioritised to 
adults ages 20-49 years 
minimised cumulative 
incidence but mortality 
and years of life lost were 
minimised with 
prioritisation given to 
adults over 60y, in most 
scenarios 
• Use of individual-level 
serological tests to 
redirect doses to 
seronegative individuals 
improved the impact of 
each dose while 
potentially reducing 
existing inequities in 
COVID-19 impact 
• Whilst maximum impact 
prioritisation strategies 
were broadly consistent 
across countries, this 
framework can be used 
Vaccine 
prioritisation 
to compare across 
contexts considering 
transmission rates, 
vaccine rollout speeds, 














• A modelling study to 
assess the merit of 
testing contacts to avert 
onward transmission and 
to replace or reduce the 
length of quarantine for 
uninfected contacts  
• In most countries, 
contacts of confirmed 
COVID-19 cases are 
currently asked to 
quarantine for 14 days 
after exposure to limit 
onward transmission but 
at a social and economic 
cost to the individual and 
wider society and 
potentially reducing 
adherence and policy 
effectiveness 
• Findings are that 
quarantine until a PCR or 
lateral flow antigen (LFA) 
test on day 7 after 
exposure (with early 
release if negative) might 
avert as much 
transmission as the 14-
day quarantine period 
• Also, daily repeated LFA 
testing of traced contacts 
for 5 days, with isolation 
only after a positive test, 
might allow for standard 
quarantine to be removed 
with a small increase in 
transmission risk offset 
by increased participation 
and adherence to 
isolation  
• Thus testing may allow 
for a substantial 
reduction in the length of, 
or replacement of 
quarantine with a small 
excess in transmission 
risk 
• Decreasing test and trace 
delays and increasing 
Quarantine, 
testing 
adherence will further 
increase the 
effectiveness of these 
strategies 
• But before policy change, 
further research is 
required to evaluate the 
potential costs (increased 
transmission risk, false 
reassurance) and 
benefits (reduction in the 
burden of quarantine, 
increased adherence) of 
such strategies 













• A cohort study to assess 
the practical performance 
of RT-PCR-based 
surveillance protocols 
and to determine the 
extent of undetected 
SARS-CoV-2 infection in 
Shenzhen, China 
• Approximately 4% of 
PCR-negative close 




on ELIZA i.e. virological 
RT-PCR testing did not 
detect approximately 30-
40% of infections among 
close contacts of 
confirmed cases 
• Seropositive contacts 
RT-PCR-negative were 
less likely to report 
symptoms that those who 
tested positive on RT-
PCR 
• Even rigorous RT-PCR 
testing protocols might 
miss a substantial 
proportion of SARS-CoV-
2 infections – maybe due 
to difficulties in 
determining the timing of 
testing in asymptomatic 
individuals for optimal 
sensitivity 
• Innovations to improve 
the accuracy of 
virological testing and 




less invasive testing are 
required 
• The study did show that 
control of community 
spread in Shenzhen, 
China was possible 
through RT-PCR-based 
surveillance and control 
protocols that include 
rapid contact tracing, 
universal RT-PCR testing 
and mandatory 2-week 
quarantine, despite the 



















• Retrospective cohort 
study of contact-tracing 
records from more than 
27,000 households in 
Wuhan to assess 
household transmissibility 
of SARS-CoV-2 and risk 
factors associated with 
infectivity and 
susceptibility to infection 
in Wuhan 
• Within households, 
children and adolescents 
were less susceptible to 
SARS-CoV-2 infection, 
but were more infectious 
once infected than 
individuals aged 20 years 
or older 
• Study confirmed higher 
susceptibility of infants 
(aged 0-1 years) to 
infection than older 
children (>=2y) 
• Although children and 
adolescents were much 
less likely to have severe 
disease, they were as 
likely as adults to develop 
symptoms 
• Pre-symptomatic cases 
were more infectious and 
individuals with 
asymptomatic infection 
80% less infectious than 
symptomatic cases 
• Isolation of cases and 
quarantining of 
household contacts away 





• Findings have 
implications for 
intervention design for 
blocking household 
transmission of SARS-
CoV-2, such as timely 
vaccination of eligible 
children when resources 
are available 
• High infectivity of children 
with SARS-CoV-2 
infection highlights the 
need for careful planning 
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22.01.2021 Effect of 
anakinra 
versus usual 














• Patients with COVID-
19 pneumonia have an 





• A multicentre, open-
label, Bayesian 
randomised clinical trial 
to determine whether 
anakinra, a 
recombinant human IL-
1 receptor antagonist, 
could improve 




• 153 patients were 
screened but 
recruitment was 
stopped after 116 
patients by the DSMB 
• Anakinra did not 




• Efficacy of anakinra 







in other selected 
groups of patients with 
more severe COVID-19 
















• A phase 2 portion of a 
randomised phase 2/3 
clinical trial with 577 
patients to assess the 




CoV-2 viral load in 
outpatients with mild to 
moderate COVID-19 
• No significant 
difference in change in 
viral load with 3 
different doses of 
bamlanivimab 
monotherapy 
compared with placebo 





SARS-CoV-2 log viral 
load at day 11 






















print (not peer 
reviewed) 
• In vitro neutralization 




• No significant impact on 
neutralizing titres against 
the B.1.1.7 (UK) variant 
relative to prior variants  
• Six-fold reduction in 
neutralizing titres against 
the B.1.351 (SA) variant 
relative to prior variants, 
but remained above 
levels that are expected 
to be protective 
• See press release below 




















• As of 15 Jan 2021, 9 
vaccines have received 
emergency use 
authorisation to be 
administered to prevent 
COVID-19 
• Preliminary analyses for 
the safety and 
immunogenicity of the 
vaccine candidate 
BBV152, manufactured 
and produced in India, in 
375 vaccinated healthy 
adults in India 
• All vaccines groups had 
similar reactogenicity 
and serological 
outcomes to the control 
group 



























• Study testing immune 
responses in patients 3 
weeks following their first 
dose of the Pfizer 
BioNTech vaccine 
BNT162b2 
• Also tested neutralising 
antibody responses 
against the B.1.1.7 (UK) 
variant compared to wild 
type 
• There was a range of 
neutralisation titres 
against wild type  
• A lower proportion of 
participants over 80y 
achieved threshold of 
neutralisation titre 
compared to those under 
80y after the first dose 
• Neutralisation titres were 
reduced against UK 
variant 
• Further work required to 
establish the impact of 
these observations on 




















• Presentation of an equity 
framework applied to COVID-
19 that sheds light on the full 
spectrum of health inequities, 
navigates their sources and 
intersections, and directs 
ethically just interventions 
• This equity map guides 
surveillance and research to 
reveal epidemiological 
uncertainties of novel diseases 
like COVID-19, recognising 
that inequities may exist where 
evidence is currently 
insufficient 
• This roadmap can steer global 
leadership towards equitable 
allocation with diverse 
strategies for diverse inequities 
Equity 
framework 
Comments, Editorials, Opinions, Blogs, News  
Publication 
date 
Title/URL Journal | Article type 
25.01.2021 In a major setback, Merck to stop developing its 
two Covid-19 vaccines and focus on therapies 
Stat news 
25.01.2021 Moderna COVID-19 vaccine retains neutralizing 
activity against emerging variants first identified 
in the U.K. and the Republic of South Africa 
Moderna | Press release 
23.01.2021 COVID-19: the intersection for education and 
health 
The Lancet | Editorial 
22.01.2021 Do not repeat mistakes from HIV in COVID-19 
response 
The Lancet HIV | Editorial  
22.01.2021 Face masks in the post-COVID-19 era: a silver 
lining for the damaged tuberculosis public health 
response? 
The Lancet Respiratory 
Medicine |  
22.01.2021 Full-dose blood thinners decreased need for life 
support and improved outcome in hospitalized 
COVID-19 patients 
NIH | News release 
21.02.2021 Optimism and caution for an inactivated COVID-
19 vaccine 
The Lancet Infectious 
Diseases | Comment 
21.01.2021 Covid: How a £20 gadget could save lives BBC News 
20.01.2021 Vaccinating children against Covid-19 – the 
lessons of measles 
NEJM | Perspective 
15.01.2021 Herd immunity by infection is not an option Science | Perspective 
08.01.2021 SARS-CoV-2 spillover events Science | Perspective 
 
  
   
 
Dashboards & Trackers 












  Diagnostics   Treatments   Vaccines 
WHO sitreps  WHO Africa  Ghana  COVID-NMA  WHO    FIND SARS-
CoV-2 Test 
Tracker 
  Global COVID-
19 Clinical Trial 
Tracker 
  CEPI 
WHO dashboard  African 
Arguments  


















Nigeria CDC  Norwegian 
Institute of Public 
Health  
Cytel   Serology-based 
tests for COVID-
19 
  Solidarity trial  COVID-19 
Oxford 
Vaccine Trial 





US NIH   Our World in 
Data: C19 
Testing 






Our World in 
Data  
  Singapore   Our World in 
Data: C19 Policy 
responses 
COVID-evidence        
Global 5050    UK   IFPRI COVID-19 
Policy Response 
Portal 
Cochrane        
CEBM, University 
of Oxford  
  US   COVID-19 
Primer 
Clinicaltrials.gov        
Humanitarian 
Data Exchange  
     NIH LitCovid  UKCDR       
Information is 
Beautiful  
     WHO COVID-19 
Database 
        
LSHTM                
HealthMap 
(cases) 
              
The Commons 
Project 
              
SeroTracker                
   
 
C19 Resource Hubs 



















LSTM Stop TB 
Partnership 








  IDA 
WHO Q&A Nigeria 
CDC 
Bulletin of the 
WHO 




















































UN Women Africa 
Evidence 
Network 





and Planning  
Norwegian Institute 
of Public Health 









JAMA Network Oxford Centre for 
Evidence-based 
Medicine 
    
UNICEF   The Lancet  HEART     
UNESCO   medRxiv and 
bioRxiv 
(Preprints) 
 UKRI     
UN WFP   NEJM  Evidence Aid     
GOARN   Oxford 
University 
Press 
 NIH     
EPI-WIN   PLoS IFPRI Resources 
and Analyses of 
C19 Impact 
    
World Bank   SAGE journals  Prevent 
Epidemics  
    
Our World in 
Data 





  Springer Nature       
Reliefweb   SSRN 
(Preprints)  













      
WorldPop           
Flowminder           





    
  
GISAID           
Online learning & events 
 Date Title/URL Online 
learning/event 
Duration Lead 
14.01.2021 Evidence to impact in 
crisis: how have we 
measured up during 
the COVID-19 
pandemic? 
Webinar 1h 30 CGD 
04.12.2020 COVID-19, supply 
chain resilience and 
global trade 
Webinar 1h CGD 
03.12.2020 More money for 
health services: What 
WHO & CGD 
Health systems 
1h 30 Joe Kutzin 
is the tole of PFM in 
the “new normal”? 
Governance & 
Financing 
01.12.2020 Solutions and support 
for the mental 
wellbeing of 
community health 
workers on the 
COVID-19 frontline 
Webinar   HSG TWG on CHWs 
with The George 
Institute for Global 
Health 
19.11.2020 Looking at the 




  SSHAP 
16.11.2020 HIFA and WHO 
collaborate to 
promote sharing of 
experience and 
expertise around the 
maintenance of 
essential health 
services during (and 
after) the pandemic 
4-week 
discussion 
starting 16 Nov 
  HIFA 
10.11.2020 COVID-19 vaccine 
predictions part 2: 
estimating the time 
before we approve 
efficacious COVID-19 
vaccines 
Online event 1h30 CGD 
16.10.2020 Financing a Global 
Public Health 
Response 
Online event 1h30 CGD 
02.10.2020 Understanding and 
Improving COVID-19 
Vaccine Portfolio 
Online event 1h30 CGD 
21.09.2020 Mitigating the 
Economic and Health 
Impact of COVID-19 
across Africa 
Online event 1h30 CGD, GF, AU 
June 2020 OpenWHO, the free, 
open-access learning 
platform for health 
emergencies, now 
offers 10 online 
courses related to 
COVID19. 












Nursing in Times of 
Crisis 
Online course 2 weeks – 
2 hours 
per week 




WHO Academy and 
WHO Info mobile 
applications 





Modelling and Policy 









11.5.2020 COVID-19 Contact 
Tracing course 
Online learning 5 hours Johns Hopkins 






5 sessions 1h 30 International Initiative 










online brief with Dr 
David Nabarro 
















training for the 
coronavirus disease 
outbreak 

































6 April 2020 COVID-19 Critical 
Care: Understanding 
and Application 





of Edinburgh & Royal 
College of Physicians 
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Rapid review methodology 
The rapid weekly search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa” OR “South Asia” OR “Developing” OR “low-income” OR “low 
income” OR “lower-middle income” OR “low and middle income” OR “LMIC” OR “LIC” OR “global south”) OR 
(“poverty”) OR (“equity” OR “equities”), restricted to articles published in the previous 2 to 3 days, in English. This 
is complemented by a search of the homepage of the following high-impact global health journals: The Lancet 
journals, New England Journal of Medicine, Nature, JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ 
Global Health, the PLoS journals and a Twitter search of their Twitter pages. A search also of preprints from bioRxiv 
and medRxiv. Please note that papers that have not been peer-reviewed are highlighted in red. All primary research 
papers that relate to the primary and secondary impacts of the COVID-19 response in LMICs, and disease control 
and health system responses are included. Articles related to tackling the secondary impacts on other sectors are 
not included. Additional commentaries, opinions, and commissioned pieces are selected based on relevance. 
 The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
About this report  
This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based research. The 
summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make 
original documents easily accessible to decision makers which, if relevant to them, they should go to before 
making decisions. The HES are not intended to replace medical or professional advice and the researcher or the 
K4D consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES 
alone. K4D services are provided by a consortium of leading organisations working in international development, 
led by the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds 
Nuffield Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), 
University of Birmingham International Development Department (IDD) and the University of Manchester 
Humanitarian and Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Foreign, Commonwealth 
and Development Office (FCDO) and its partners in support of pro-poor programmes. Except 
where otherwise stated, it is licensed for non-commercial purposes under the terms of the 
Open Government Licence v3.0. K4D cannot be held responsible for errors, omissions or 
any consequences arising from the use of information contained in this health evidence 
summary. Any views and opinions expressed do not necessarily reflect those of FCDO, K4D 
or any other contributing organisation.  
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